SCHEMBL20913971

SCHEMBL20913971

Cc1nc(-c2c(C)[nH]c3c(-c4ccccc4)c(C(F)(F)F)nn3c2=O)[nH]c1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ ARF6 P62330 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HPGD P15428 3/20 0.36
▸ PLAT P00750 2/20 0.36
▸ PIN1 Q13526 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HTT P42858 2/20 0.35
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ DCTPP1 Q9H773 1/20 0.34
▸ KCNQ3 O43525 1/20 0.34
▸ KCNQ2 O43526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914113 0.86 KDM4E (0.45) POLBKDM4EALDH1A1MEN1KMT2A
SCHEMBL20914122 0.86 KDM4E (0.43) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20913938 0.85 TNKS (0.50) POLBKDM4EALDH1A1HPGDMAPT
SCHEMBL20819063 0.83 POLB (0.44) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20914284 0.83 HSD17B10 (0.41) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20819034 0.82 POLB (0.47) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20914410 0.81 POLB (0.46) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20819077 0.81 POLB (0.46) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20931250 0.80 LMNA (0.44) POLBKDM4EARF6ALDH1A1MEN1
SCHEMBL20819045 0.80 POLB (0.45) POLBKDM4EARF6ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 POLB 4311/4885KDM4E 1922/4885ARF6 3310/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 POLB 4311/4885KDM4E 1922/4885ARF6 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback